Search research articles
Contact Us
Filters
Showing results (91-100 of 106) with videos related to
Page
of 11
Sort By:
NPJ Breast Cancer
|
May 14, 2025
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification
Kristin Galas, Moritz Gleitsmann, Julia Rey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2024
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Paul Jank, Thomas Karn, Marion van Mackelenbergh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2023
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Terence M Williams, Andreas Schneeweiss, Christian Jackisch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2023
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Peter A Fasching, Christopher Szeto, Carsten Denkert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2019
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Sibylle Loibl, Denise Treue, Jan Budczies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2020
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Thomas Karn, Tobias Meissner, Karsten E Weber, et al.
The Lancet. Oncology
|
December 14, 2017
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, et al.
International Journal of Cancer
|
January 30, 2019
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial
Melanie Janning, Volkmar Müller, Eik Vettorazzi, et al.
JAMA Oncology
|
July 18, 2017
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial
Eric Hahnen, Bianca Lederer, Jan Hauke, et al.
The Lancet. Oncology
|
November 27, 2025
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials
Fabio Conforti, Johannes Holtschmidt, Valentina Nekljudova, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 106) with videos related to
Sort By:
Page
of 11
NPJ Breast Cancer
|
May 14, 2025
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification
Kristin Galas, Moritz Gleitsmann, Julia Rey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2024
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Paul Jank, Thomas Karn, Marion van Mackelenbergh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2023
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Terence M Williams, Andreas Schneeweiss, Christian Jackisch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2023
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Peter A Fasching, Christopher Szeto, Carsten Denkert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2019
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Sibylle Loibl, Denise Treue, Jan Budczies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2020
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Thomas Karn, Tobias Meissner, Karsten E Weber, et al.
The Lancet. Oncology
|
December 14, 2017
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, et al.
International Journal of Cancer
|
January 30, 2019
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial
Melanie Janning, Volkmar Müller, Eik Vettorazzi, et al.
JAMA Oncology
|
July 18, 2017
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial
Eric Hahnen, Bianca Lederer, Jan Hauke, et al.
The Lancet. Oncology
|
November 27, 2025
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials
Fabio Conforti, Johannes Holtschmidt, Valentina Nekljudova, et al.
Page
of 11